Protocol Ledger

NCT07543120 · Phase II · RECRUITING

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

Interventional Phase II clinical trial protocol NCT07543120 sponsored by Novartis in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-07 Enrollment: 323 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07543120
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)323 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07543120
Protocol FieldVerified Registry Value
NCT IdentifierNCT07543120
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment323 participants (ESTIMATED)
Registered Start Date2026-05-07
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI